Spyre Therapeutics, Inc. (SYRE) stock
SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
$101.46+7.65 (+8.15%)
Close on Nov 18, 2026Market cap $8.95BP/E –Yield –
Spyre Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Spyre Therapeutics's price to sales ratio was 99.5× on Jan 31, 2024, against 5.3× a year earlier. Over the last 4 years it ranged from 1.0× to 108.7×, with a median of 30.7×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2024 | Jan 31, 2024 | 99.5× | +16.9 |
| 2023 | Dec 29, 2023 | 82.7× | +77.9 |
| 2022 | Dec 30, 2022 | 4.8× | −103.9 |
| 2019 | Jul 31, 2019 | 108.7× | +77.8 |
| 2018 | Dec 31, 2018 | 30.8× | – |
See a number that looks wrong?